Tesavel: Uses, Dosage & Side Effects
DPP-4 inhibitor (sitagliptin) for type 2 diabetes mellitus
Quick Facts About Tesavel
Key Takeaways About Tesavel
- Same active substance as Januvia: Tesavel contains sitagliptin, the same active ingredient found in Januvia, Xelevia and Ristaben – all marketed by Merck Sharp & Dohme (MSD)
- 25 mg for kidney impairment: The 25 mg strength is specifically dosed for adults with severe renal impairment (eGFR < 30 mL/min) or those on dialysis, where a reduced daily dose is required
- Once-daily oral dosing: Tesavel is taken once daily, with or without food, offering convenient and flexible administration
- Low risk of hypoglycemia: When used alone or with metformin, sitagliptin has a low risk of causing dangerously low blood sugar thanks to its glucose-dependent mechanism of action
- Cardiovascular safety proven: The TECOS trial demonstrated that sitagliptin does not increase the risk of major cardiovascular events in adults with established type 2 diabetes
What Is Tesavel and What Is It Used For?
Tesavel is a brand-name medicine that contains sitagliptin, a DPP-4 inhibitor used to lower blood sugar in adults with type 2 diabetes. It works by boosting incretin hormones that stimulate insulin release after eating and reduce the liver's glucose production. Tesavel is taken once daily as an oral tablet, either alone or combined with other diabetes medications.
Tesavel belongs to a class of medications known as DPP-4 inhibitors, sometimes called gliptins. The active substance, sitagliptin, was the first DPP-4 inhibitor approved for the treatment of type 2 diabetes, first authorised by the U.S. Food and Drug Administration (FDA) in 2006 and by the European Medicines Agency (EMA) in 2007 under the brand name Januvia. Tesavel is one of several brand names under which sitagliptin is marketed globally by Merck Sharp & Dohme (MSD) and its partners; others include Januvia, Xelevia, and Ristaben, all of which are therapeutically equivalent.
The medicine works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down incretin hormones in the body. The two key incretin hormones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By preventing their rapid degradation, Tesavel allows these hormones to remain active longer, leading to increased insulin secretion from the pancreas after meals and decreased glucagon release – both of which help lower blood glucose.
A key advantage of sitagliptin's mechanism of action is that it works in a glucose-dependent manner. This means the drug primarily stimulates insulin release when blood sugar is elevated (for example, after a meal) and has little effect when blood sugar is normal or low. This characteristic is the main reason Tesavel carries a low intrinsic risk of hypoglycemia when used as monotherapy or in combination with metformin.
Your doctor may prescribe Tesavel when diet, exercise, and weight management alone are not sufficient to control your blood sugar, or when other medications such as metformin alone do not provide adequate glycemic control. Tesavel can be prescribed as standalone therapy (when metformin is not tolerated or contraindicated) or in combination with metformin, sulfonylureas (such as glimepiride or glipizide), pioglitazone, or insulin.
What is type 2 diabetes?
Type 2 diabetes is a chronic metabolic condition in which your body either does not produce enough insulin or cannot effectively use the insulin it produces – a phenomenon known as insulin resistance. Insulin is a hormone produced by the pancreas that allows glucose (sugar) from the food you eat to enter your cells and be used as energy. When insulin function is impaired, glucose builds up in the bloodstream, leading to elevated blood sugar levels (hyperglycemia).
Over time, persistently high blood sugar can damage blood vessels and nerves throughout the body, increasing the risk of serious complications including coronary artery disease, stroke, chronic kidney disease (diabetic nephropathy), retinal damage (diabetic retinopathy), and nerve damage (diabetic neuropathy). Effective blood sugar management through lifestyle modifications and medication significantly reduces these risks. According to the American Diabetes Association (ADA) Standards of Care 2025, maintaining an HbA1c level below 7% is a reasonable target for most adults with diabetes, although individualised targets are recommended based on age, comorbidities, and hypoglycemia risk.
Unlike sulfonylureas or insulin, which directly stimulate insulin secretion regardless of blood sugar levels, Tesavel enhances the body's natural incretin system and works primarily when blood sugar is elevated. This makes clinically significant hypoglycemia uncommon during monotherapy. Tesavel is also weight-neutral – it generally does not cause weight gain or loss, which is an advantage over some older diabetes treatments such as sulfonylureas and certain insulins.
Why a 25 mg strength?
The 25 mg strength of Tesavel is the lowest available dose of sitagliptin. It is principally prescribed for patients with severe renal impairment or end-stage renal disease (including those on hemodialysis or peritoneal dialysis). Sitagliptin is eliminated largely unchanged by the kidneys through active tubular secretion, and impaired kidney function reduces its clearance, increasing plasma exposure. To maintain a plasma drug level comparable to that seen in patients with normal kidney function taking 100 mg daily, the dose is reduced in stepwise fashion based on estimated glomerular filtration rate (eGFR).
What Should You Know Before Taking Tesavel?
Do not take Tesavel if you are allergic to sitagliptin or any of its ingredients. Tell your doctor about any history of pancreatitis, kidney disease, or gallstones. Tesavel should not be used during pregnancy or breastfeeding, and is not recommended for children and adolescents under 18 years of age.
Before starting treatment with Tesavel, it is essential that your healthcare provider has a complete picture of your medical history and all current medications, including over-the-counter products and herbal supplements. Honest and complete information helps ensure that Tesavel is both safe and appropriate for you.
Contraindications
You should not take Tesavel if you have a known allergy (hypersensitivity) to sitagliptin or to any of the other ingredients in the tablets. Serious allergic reactions including anaphylaxis, angioedema (deep swelling beneath the skin), and severe cutaneous reactions such as Stevens-Johnson syndrome have been reported during post-marketing surveillance. If you have previously experienced any allergic reaction to sitagliptin or a related DPP-4 inhibitor, you must not take Tesavel again.
Tesavel is not appropriate for type 1 diabetes or diabetic ketoacidosis (DKA). Type 1 diabetes requires insulin therapy because the pancreas produces little or no insulin; DPP-4 inhibitors cannot replace insulin in these patients. If you have elevated ketone levels in your blood or urine along with high blood sugar, rapid weight loss, nausea, or vomiting, contact your healthcare provider immediately as these may be signs of diabetic ketoacidosis – a medical emergency.
Warnings and Precautions
Inform your doctor before taking Tesavel if you have or have previously had any of the following conditions:
- Pancreatitis: Cases of acute pancreatitis have been reported in patients taking sitagliptin, including necrotising and haemorrhagic forms. If you have a history of pancreatitis, your doctor will weigh the risks and benefits carefully. Risk factors for pancreatitis include gallstones, alcohol dependence, and very high triglyceride levels.
- Kidney disease: Because sitagliptin is cleared by the kidneys, your doctor will assess your renal function before prescribing Tesavel and may monitor it periodically throughout treatment. The 25 mg strength is specifically used for patients with severe renal impairment or dialysis.
- Bullous pemphigoid: Rare cases of this autoimmune blistering skin disorder have been reported with DPP-4 inhibitors. If you develop tense blisters, skin erosions, or ulcers, stop taking Tesavel and contact your doctor.
- Heart failure: Although the TECOS cardiovascular outcomes trial showed no increased risk of heart failure hospitalisation with sitagliptin, patients with a history of heart failure should be monitored. Note that the DPP-4 inhibitors saxagliptin and alogliptin have different heart-failure signals – do not assume class-wide equivalence.
- History of angioedema with ACE inhibitors or other medications: inform your doctor, as the risk with DPP-4 inhibitors may be increased.
When Tesavel is combined with a sulfonylurea or insulin, the risk of hypoglycemia (low blood sugar) increases significantly. To minimise this, your doctor may reduce the dose of the sulfonylurea or insulin when adding Tesavel. Typical symptoms of hypoglycemia include sweating, shakiness, rapid heartbeat, hunger, confusion, blurred vision, and dizziness. When used alone or with metformin only, Tesavel is unlikely to cause hypoglycemia.
Children and Adolescents
Tesavel is not recommended for use in children or adolescents under 18 years of age. A randomised controlled trial of sitagliptin in patients aged 10 to 17 years with type 2 diabetes did not demonstrate significant reductions in HbA1c compared with placebo. The safety and efficacy of sitagliptin in children under 10 years have not been established. For paediatric type 2 diabetes, metformin and insulin remain the primary pharmacological options, supplemented by lifestyle interventions.
Pregnancy and Breastfeeding
Tesavel should not be used during pregnancy. There is insufficient clinical data from pregnant women to establish the safety of sitagliptin during pregnancy, and animal reproductive studies have shown some adverse effects at high doses. If you are pregnant, planning to become pregnant, or discover you are pregnant while taking Tesavel, consult your healthcare provider immediately about switching to a pregnancy-safe alternative. Insulin is generally the preferred treatment for managing diabetes in pregnancy, and metformin is used selectively in certain circumstances.
It is not known whether sitagliptin passes into human breast milk, although animal data suggest that it does. As a precaution, Tesavel should not be used during breastfeeding. Discuss alternative treatment options with your healthcare provider if you are breastfeeding or planning to breastfeed.
Driving and Operating Machinery
Tesavel has no or negligible direct effect on the ability to drive or operate machinery. However, dizziness and drowsiness have occasionally been reported, which may impair driving and operating machines safely. In addition, when Tesavel is used in combination with a sulfonylurea or insulin, hypoglycemia may occur, which can impair concentration and reaction time. Exercise caution until you know how the medication affects you, and check your blood glucose if you feel unwell while driving.
How Does Tesavel Interact with Other Drugs?
Tesavel has relatively few clinically significant drug interactions. The most important interaction is with digoxin, which may require monitoring. When combined with sulfonylureas or insulin, doses of those medications may need to be reduced to prevent low blood sugar.
Sitagliptin is primarily eliminated by the kidneys through active tubular secretion. It is not extensively metabolised by liver enzymes (cytochrome P450) and does not significantly inhibit or induce CYP enzymes, which limits its potential for drug-drug interactions. However, there are still several important interactions to be aware of.
Always tell your doctor or pharmacist about all medications you are taking, have recently taken, or plan to take. This includes prescription drugs, over-the-counter medications, herbal supplements, and vitamins.
| Interacting Drug | Effect | Clinical Significance | Recommendation |
|---|---|---|---|
| Digoxin | Slight increase in digoxin plasma levels (AUC +11%, Cmax +18%) | Moderate | Monitor digoxin levels; dose adjustment may be needed |
| Sulfonylureas (glimepiride, glipizide, glyburide) | Increased risk of hypoglycemia | Major | Consider reducing sulfonylurea dose when adding Tesavel |
| Insulin | Increased risk of hypoglycemia | Major | Consider reducing insulin dose when adding Tesavel |
| Metformin | Complementary glucose-lowering; no pharmacokinetic interaction | Beneficial | Safe combination; standard doses of both drugs can be used |
| Cyclosporine | May increase sitagliptin exposure via P-glycoprotein inhibition | Moderate | Monitor; no routine dose change recommended |
| ACE inhibitors | Possible additive risk of angioedema | Low–Moderate | Inform patient of angioedema signs; discontinue if occurs |
Major Interactions
The most clinically important interactions occur when Tesavel is combined with other blood-sugar-lowering medications that carry a risk of hypoglycemia on their own. Sulfonylureas (such as glimepiride, glipizide, and glyburide) and insulin both directly stimulate insulin release or replace it, and adding Tesavel can amplify the glucose-lowering effect. Your prescriber should consider reducing the dose of the sulfonylurea or insulin when starting Tesavel to prevent episodes of low blood sugar, particularly in elderly patients, those with renal impairment, or those with a history of severe hypoglycemia.
Minor Interactions
Co-administration of sitagliptin with digoxin resulted in a small increase in the area under the curve (AUC) of digoxin by approximately 11% and peak plasma concentration (Cmax) by approximately 18%. These increases are generally not considered clinically significant for most patients, but digoxin has a narrow therapeutic index. Therefore, patients receiving both medications should be monitored for signs of digoxin toxicity (such as nausea, visual disturbances, and arrhythmias), and digoxin dose adjustments may occasionally be necessary based on serum digoxin levels.
No significant pharmacokinetic interactions have been observed with commonly co-prescribed medications including metformin, rosiglitazone, glyburide, simvastatin, warfarin, or oral contraceptives. Tesavel can generally be combined safely with these medications without routine dose adjustments, although clinical monitoring is always advisable.
What Is the Correct Dosage of Tesavel?
The standard maintenance dose of sitagliptin is 100 mg once daily, but Tesavel 25 mg is specifically used in adults with severe renal impairment (eGFR below 30 mL/min) or those on dialysis. Adults with moderate renal impairment typically take 50 mg once daily. Take the tablet once daily, with or without food, at the same time each day.
Always take Tesavel exactly as your doctor has prescribed. Do not change the dose or stop taking the medicine without consulting your healthcare provider. The correct dose is determined primarily by your kidney function, which your doctor will assess using the estimated glomerular filtration rate (eGFR) calculated from a blood creatinine test.
| Patient Group | Kidney Function (eGFR) | Recommended Dose | Frequency |
|---|---|---|---|
| Adults – normal or mild impairment | eGFR ≥ 45 mL/min | 100 mg | Once daily |
| Adults – moderate impairment | eGFR 30–44 mL/min | 50 mg | Once daily |
| Adults – severe impairment / dialysis (Tesavel 25 mg) | eGFR < 30 mL/min, incl. hemodialysis & peritoneal dialysis | 25 mg | Once daily |
| Elderly (≥ 65 years) | Dose based on kidney function | As above per eGFR | Once daily |
| Children (< 18 years) | N/A | Not recommended | N/A |
Adults
For adults with severe renal impairment or those on dialysis, the recommended dose of Tesavel is 25 mg once daily. The tablet can be taken with or without food, at any time of day, although it is advisable to take it at approximately the same time each day to maintain consistent blood levels. For patients receiving hemodialysis, Tesavel may be administered irrespective of the timing of dialysis, as sitagliptin is not significantly removed by dialysis (only about 13.5% is removed in a 3–4 hour session).
When Tesavel is added to an existing regimen that includes a sulfonylurea or insulin, your doctor may reduce the dose of the sulfonylurea or insulin to lower the risk of hypoglycemia. No dose adjustment is typically required when combining sitagliptin with metformin or pioglitazone alone.
Diet and exercise play a vital role in managing type 2 diabetes and should be continued alongside Tesavel therapy. Your healthcare provider will likely recommend a balanced diet (such as a Mediterranean or DASH pattern), regular physical activity of at least 150 minutes per week, and periodic blood glucose and HbA1c monitoring to ensure optimal glycemic control.
Children
Tesavel is not recommended for children and adolescents under 18 years of age. A clinical trial in paediatric patients aged 10 to 17 years with type 2 diabetes did not demonstrate efficacy, as sitagliptin did not significantly reduce HbA1c compared with placebo over 20 weeks. No data are available for children under 10 years. For paediatric patients with type 2 diabetes, metformin and insulin remain the primary pharmacological treatment options as recommended by international guidelines including the ADA and the International Society for Pediatric and Adolescent Diabetes (ISPAD). More recently, some GLP-1 receptor agonists have been approved for adolescents.
Elderly
No dose adjustment based on age alone is necessary for elderly patients (≥ 65 years). However, because kidney function naturally declines with age, elderly patients are more likely to require a reduced dose based on their estimated glomerular filtration rate. Elderly patients on dialysis or with severe renal impairment may therefore be prescribed Tesavel 25 mg. Your doctor will assess your kidney function before prescribing and may perform periodic monitoring. In clinical trials, sitagliptin was generally well tolerated in older adults, with a safety profile comparable to that seen in younger patients.
Missed Dose
If you forget to take a dose of Tesavel, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one, as this could increase the risk of side effects. If you have difficulty remembering to take your medication, consider setting a daily alarm on your phone, linking the dose to a regular daily routine (such as breakfast), or using a pill organiser.
Overdose
If you accidentally take more Tesavel than prescribed, contact your doctor or local poison control centre immediately. In controlled clinical trials, single doses of up to 800 mg of sitagliptin were generally well tolerated. There is limited clinical experience with doses above 800 mg, but some QT-interval prolongation may occur at very high exposures. Treatment of overdose is supportive – including general supportive measures such as removal of unabsorbed material from the gastrointestinal tract, clinical monitoring (including ECG), and initiating supportive therapy as required. Sitagliptin is not efficiently removed by hemodialysis.
Discontinuing Tesavel abruptly can lead to a rise in blood sugar levels and worsening glycemic control. If you wish to stop or change your diabetes medication, always discuss this with your healthcare provider first. They can help you transition safely to an alternative therapy and ensure your blood sugar remains well controlled during the change.
What Are the Side Effects of Tesavel?
Common side effects of Tesavel include headache, upper respiratory tract infection, stuffy or runny nose, and joint pain. When combined with other diabetes drugs, low blood sugar may occur. Rare but serious side effects include pancreatitis, severe allergic reactions, and bullous pemphigoid. Stop taking Tesavel and seek immediate medical attention for severe abdominal pain or signs of a serious allergic reaction.
Like all medicines, Tesavel can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and typically resolve on their own without requiring treatment discontinuation. It is important to be aware of both common and serious side effects so you can take appropriate action if they occur.
- Severe and persistent abdominal pain that may radiate to the back, with or without nausea and vomiting – these could be signs of acute pancreatitis
- Severe allergic reaction: rash, hives, blisters, peeling skin, or swelling of the face, lips, tongue, or throat causing difficulty breathing or swallowing (anaphylaxis or angioedema)
- Tense blisters or skin erosions – possible bullous pemphigoid
Common Side Effects
May affect up to 1 in 10 people
- Low blood sugar (hypoglycemia) – especially when combined with sulfonylureas or insulin
- Headache
- Upper respiratory tract infection
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Osteoarthritis (joint inflammation)
- Pain in arms or legs
- Nausea (particularly when combined with metformin)
- Flatulence (gas)
- Constipation
- Swelling of hands or feet (peripheral edema) – when used with pioglitazone
Uncommon Side Effects
May affect up to 1 in 100 people
- Dizziness
- Itching (pruritus)
- Abdominal pain
- Diarrhea
- Drowsiness
- Dry mouth (when used with insulin)
Rare Side Effects
May affect up to 1 in 1,000 people
- Decreased platelet count (thrombocytopenia)
Not Known (frequency cannot be estimated)
Reported from post-marketing surveillance
- Severe allergic reactions (anaphylaxis, angioedema)
- Acute pancreatitis (including necrotising and haemorrhagic forms)
- Acute kidney injury (sometimes requiring dialysis)
- Bullous pemphigoid (blistering skin condition)
- Interstitial lung disease
- Vomiting
- Joint pain (arthralgia), sometimes severe
- Muscle pain (myalgia)
- Back pain
- Rash, hives (urticaria)
- Cutaneous vasculitis
- Stevens-Johnson syndrome
Side Effects by Combination Therapy
The type and frequency of side effects can vary depending on which other diabetes medications you take alongside Tesavel. When combined with metformin, gastrointestinal symptoms such as nausea, flatulence, and vomiting are more commonly reported, as these are typical side effects of metformin itself. When combined with a sulfonylurea and metformin, hypoglycemia occurs more frequently and is classified as very common (affecting more than 1 in 10 people). When combined with insulin, flu-like symptoms and dry mouth have been reported. When combined with pioglitazone, peripheral edema (swelling of hands and feet) is more common.
Most side effects of Tesavel are mild and transient. However, if any side effect becomes severe, persists, or causes you concern, consult your healthcare provider. Your doctor can help determine whether the side effect is related to Tesavel or another medication, and may adjust your treatment accordingly. Do not stop the medication on your own without medical advice, as this can worsen your blood sugar control.
Reporting Side Effects
Reporting suspected adverse reactions after a medicine has been authorised is important. It allows ongoing monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients can report side effects to their national drug regulatory authority, such as the FDA in the United States (via the MedWatch programme), the MHRA in the United Kingdom (via the Yellow Card Scheme), Health Canada (via MedEffect), the TGA in Australia, or other national regulators in Europe (who forward reports to the EMA).
How Should You Store Tesavel?
Store Tesavel tablets at room temperature, away from moisture and direct sunlight. Keep them in the original blister pack until use. No special temperature requirements are needed. Keep out of reach of children and do not use after the expiration date printed on the carton.
Proper storage of your medication is essential to maintain its effectiveness and safety throughout its shelf life. Follow these guidelines for storing Tesavel:
- Temperature: No special temperature requirements. Store at room temperature, typically below 30°C (86°F). Avoid storing in bathrooms or kitchens where temperature and humidity can fluctuate.
- Moisture: Keep the tablets in their original blister packaging until you are ready to take them. The packaging protects against moisture, which can degrade the medication.
- Light: Avoid exposing the tablets to direct sunlight or excessive heat, such as a car dashboard.
- Children: Always store medications out of the sight and reach of children to prevent accidental ingestion.
- Expiration date: Do not use Tesavel after the expiration date printed on the blister pack and carton (marked as "EXP" or "Use by"). The expiration date refers to the last day of the indicated month.
Do not dispose of medications by flushing them down the toilet or throwing them in household waste. Ask your pharmacist about local medication take-back programmes or proper disposal methods. These measures help protect the environment and prevent accidental exposure of others, including children and pets.
What Does Tesavel Contain?
Each Tesavel 25 mg film-coated tablet contains sitagliptin (as sitagliptin phosphate monohydrate) as the active ingredient, along with inactive ingredients including microcrystalline cellulose, calcium hydrogen phosphate, croscarmellose sodium, and magnesium stearate. The tablet is film-coated and essentially sodium-free.
Active Ingredient
The active substance in Tesavel tablets is sitagliptin, present in the form of sitagliptin phosphate monohydrate. Each Tesavel 25 mg tablet contains an amount of sitagliptin phosphate monohydrate equivalent to 25 mg of free sitagliptin base. Sitagliptin is the compound responsible for the therapeutic blood-sugar-lowering effect through inhibition of the DPP-4 enzyme.
Inactive Ingredients (Excipients)
The inactive ingredients help form the tablet, aid disintegration, protect the active ingredient, and provide the characteristic appearance:
- Tablet core: Microcrystalline cellulose (E460), calcium hydrogen phosphate (anhydrous), croscarmellose sodium (E468), magnesium stearate (E470b), and sodium stearyl fumarate
- Film coating: Poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), red iron oxide (E172), and yellow iron oxide (E172)
Tesavel tablets contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially "sodium-free". This is relevant for patients on a sodium-restricted diet, such as those with hypertension or heart failure.
Tablet Appearance and Packaging
- Tesavel 25 mg: Pink, round, film-coated tablet with a flat edge, approximately 6–6.4 mm in diameter, with "221" debossed on one side
Tablets are supplied in opaque PVC/PE/PVDC-aluminium or OPA/aluminium/PVC/aluminium blister packs. Pack sizes commonly available include 14, 28, 30, 56, 84, 90, 98, and 100 film-coated tablets, although not all pack sizes may be marketed in every country. Check your local prescribing information or speak with your pharmacist for available pack sizes in your region.
Frequently Asked Questions About Tesavel
Tesavel (active ingredient: sitagliptin) is a DPP-4 inhibitor used to treat type 2 diabetes mellitus in adults. It works by increasing insulin production after meals and reducing the amount of glucose produced by the liver. It can be used alone when diet and exercise are insufficient, or in combination with other diabetes medications such as metformin, sulfonylureas, pioglitazone, or insulin. Tesavel is not used for type 1 diabetes or diabetic ketoacidosis.
The 25 mg strength of Tesavel is specifically intended for adults with severe renal impairment (eGFR below 30 mL/min) or those receiving hemodialysis or peritoneal dialysis. Because sitagliptin is eliminated primarily by the kidneys, patients with impaired renal function require a lower dose to avoid accumulation and maintain safe drug levels. Other strengths (50 mg and 100 mg) of sitagliptin exist under different brand names and may be prescribed for patients with better kidney function.
Common side effects include headache, upper respiratory tract infection, stuffy or runny nose and sore throat, osteoarthritis, and pain in the arms or legs. When combined with other diabetes medications, low blood sugar (hypoglycemia) is also common. Gastrointestinal symptoms like nausea, flatulence, and constipation may occur, particularly when used with metformin. Most side effects are mild and resolve on their own without requiring discontinuation of treatment.
Cases of acute pancreatitis have been reported in patients taking sitagliptin-containing medicines, including Tesavel, during clinical trials and post-marketing surveillance. While a direct causal relationship has not been definitively established, you should stop taking Tesavel and contact your doctor immediately if you experience severe, persistent abdominal pain that may radiate to the back, with or without nausea and vomiting. Risk factors include a history of pancreatitis, gallstones, alcohol dependence, and very high triglyceride levels.
Tesavel, Januvia, and Xelevia all contain the same active ingredient – sitagliptin – and are marketed by Merck Sharp & Dohme (MSD) or its partners. They are therapeutically equivalent and produce the same clinical effects with the same dosing, safety profile, and drug interactions. The brand name used depends on the country and local marketing authorisation. You should not combine these medicines, as doing so would result in a double dose of sitagliptin.
Yes, sitagliptin and metformin are one of the most commonly prescribed combinations for type 2 diabetes. The two drugs work through complementary mechanisms: metformin reduces glucose production by the liver and improves insulin sensitivity, while sitagliptin enhances incretin hormones to boost insulin secretion after meals. This combination provides better blood sugar control than either drug alone. Fixed-dose combination tablets containing sitagliptin and metformin are also available (e.g. Janumet) in many countries.
Tesavel should not be used during pregnancy. There is insufficient data from human studies, and animal studies at high doses have shown some reproductive effects. If you are pregnant, planning a pregnancy, or discover you are pregnant while taking Tesavel, contact your doctor immediately. Insulin is generally the preferred treatment for managing blood sugar during pregnancy, and metformin may be used in selected circumstances. Tesavel should also not be used while breastfeeding, as it is not known whether it passes into human breast milk in significant amounts.
Tesavel (sitagliptin) is considered weight-neutral, meaning it generally does not cause significant weight gain or weight loss. This is an advantage compared to some other diabetes medications such as sulfonylureas, insulin, and thiazolidinediones, which can lead to weight gain. In clinical trials, sitagliptin was associated with minimal changes in body weight. If weight management is a priority in your diabetes treatment plan, discuss this with your doctor, who may consider alternatives such as GLP-1 receptor agonists or SGLT2 inhibitors that support weight loss.
All information is based on international medical guidelines and peer-reviewed research: EMA Summary of Product Characteristics for Januvia/sitagliptin, FDA prescribing information, ADA Standards of Care in Diabetes 2025, NICE Guidelines for Type 2 Diabetes Management (NG28), the TECOS cardiovascular outcomes trial published in the New England Journal of Medicine, and the WHO Model List of Essential Medicines. All medical claims follow evidence level 1A, the highest quality of evidence based on systematic reviews and randomised controlled trials.
References
- European Medicines Agency (EMA). Januvia (sitagliptin) – Summary of Product Characteristics. Last updated 2024. EMA – Januvia EPAR
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement 1). ADA Standards of Care 2025
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS). N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
- National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management (NG28). Last updated 2024. NICE NG28
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. 2023. WHO Essential Medicines List
- U.S. Food and Drug Administration (FDA). Januvia (sitagliptin) Prescribing Information. FDA Prescribing Information
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642–653. doi:10.1038/s41574-020-0399-8
- Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536.
- British National Formulary (BNF). Sitagliptin monograph. Joint Formulary Committee. BMJ Group and Pharmaceutical Press, London.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetologia. 2022;65(12):1925–1966.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specialising in endocrinology, diabetology, and clinical pharmacology. Our editorial process ensures that all content meets the highest standards of medical accuracy, following the GRADE evidence framework and international clinical guidelines.
All drug information is verified against the European Medicines Agency (EMA) Summary of Product Characteristics, FDA prescribing information, and current clinical guidelines (ADA, NICE, WHO).
Evidence Level 1A – based on systematic reviews, meta-analyses of randomised controlled trials, and landmark cardiovascular outcomes trials (TECOS).
No pharmaceutical company sponsorship or advertising. All content is editorially independent with no commercial funding or conflicts of interest.
This article is reviewed and updated regularly to reflect the latest clinical evidence, regulatory changes, and guideline updates.